Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunoablative Conditioning for Autologous BMT in MS
NCT02529839Unknown
- Sponsor
- Hadassah Medical Organization
- Start
- Oct 2015
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Open-label, single-arm trial of fludarabine, cyclophosphamide and alemtuzumab in multiple sclerosis (MS), sponsored by Hadassah Medical Organization. Primary endpoints: Engraftment parameters of Neutrophils and Platelets at 1 year and Transplant related mortality at 100 days. Status: unknown.
02
Drugs
fludarabinecyclophosphamidealemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02529839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529839.